PMID- 34703851 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240214 IS - 2352-3409 (Electronic) IS - 2352-3409 (Linking) VI - 39 DP - 2021 Dec TI - The characteristics of mitral regurgitation: Data from patients admitted following acute myocardial infarction. PG - 107451 LID - 10.1016/j.dib.2021.107451 [doi] LID - 107451 AB - Data were collected on patients admitted to the Queen Elizabeth Hospital Birmingham with type-1 myocardial infarction during 2016 and 2017 inclusively, who were treated by percutaneous intervention and had pre-discharge transthoracic echocardiography. The data were obtained from prospectively maintained hospital databases and records. Echocardiography was performed and reported contemporaneously by accredited echocardiographers. The purpose was to understand the prevalence and characteristics of mitral regurgitation (MR) after acute MI, including patients with ST-elevation (STEMI) and non-ST elevation MI (NSTEMI). MR was observed in 294/1000 patients with the following relative severities: mild = 76%, moderate = 21%, severe = 3% [1]. MR was graded by multiparametric quantification including proximal isolvelocity surface area (PISA), vena contracta (VC), effective regurgitant orifice area (EROA) and regurgitant volume (RVol). Amongst all patients with MR (n=294), PISA was performed in 89/294 (30%), VC 75/294 (26%), EROA in 53/294 (18%) and RVol in 26/294 (9%). Amongst patients with moderate or severe MR (n=70), PISA was performed in 57/70 (81%), VC in 55/70 (79%), EROA in 46/70 (66%) and RVol in 25/70 (36%). Characteristics of MR following acute MI were also assessed including frequency of reported leaflet thickness (259/294 = 88%) and mitral annular calcification (102/294 = 35%). Furthermore, the effect of MI on pre-existing MR was investigated and patients with pre-existing MR who continue to have MR after acute MI were found to have progression of MR by one grade in approximately 25% of cases. Finally, using Cox proportional hazards univariate analysis, significant factors associated with mortality in patients with MR post-MI include age (HR 1.065; 95% CI 1.035-1.096; p<0.001), creatinine clearance, (HR 0.981; 95% CI 0.971-0.991; p<0.001), left ventricular ejection fraction (LVEF) (HR 0.966; 95% CI 0.948-0.984; p<0.001), indexed left ventricular end-diastolic volume (LVEDVi) (HR 1.016; 95% CI 1.003-1.029; p=0.018), indexed left ventricular end-systolic volume (LVESVi) (HR 1.021; 95% CI 1.008-1.034; p=0.001), indexed left atrial volume (HR 1.026; 95% CI 1.012-1.039; p<0.001), and those with intermediate likelihood of pulmonary hypertension (pHTN) (HR 2.223; 95% CI 1.126-4.390; p=0.021); or high likelihood of pHTN (HR 5.626; 95% CI 2.189-14.461; p<0.001). Age and LVEF were found to be independent predictors of mortality on multivariate analysis [1]. CI - (c) 2021 The Authors. Published by Elsevier Inc. FAU - Sharma, Harish AU - Sharma H AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. AD - Department of Cardiology, University Hospitals Birmingham, Birmingham, UK. FAU - Radhakrishnan, Ashwin AU - Radhakrishnan A AD - Department of Cardiology, University Hospitals Birmingham, Birmingham, UK. FAU - Nightingale, Peter AU - Nightingale P AD - Institute of Translational Medicine, University Hospitals Birmingham, Birmingham, UK. FAU - Brown, Samuel AU - Brown S AD - Medical School, College of Medical and Dental Sciences, University of Birmingham, UK. FAU - May, John AU - May J AD - Department of Cardiology, University Hospitals Birmingham, Birmingham, UK. FAU - O'Connor, Kieran AU - O'Connor K AD - Department of Cardiology, University Hospitals Birmingham, Birmingham, UK. FAU - Shakeel, Iqra AU - Shakeel I AD - Medical School, College of Medical and Dental Sciences, University of Birmingham, UK. FAU - Zia, Nawal AU - Zia N AD - Medical School, College of Medical and Dental Sciences, University of Birmingham, UK. FAU - Doshi, Sagar N AU - Doshi SN AD - Department of Cardiology, University Hospitals Birmingham, Birmingham, UK. FAU - Townend, Jonathan N AU - Townend JN AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. AD - Department of Cardiology, University Hospitals Birmingham, Birmingham, UK. FAU - Myerson, Saul G AU - Myerson SG AD - Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK. FAU - Kirchhof, Paulus AU - Kirchhof P AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. AD - Department of Cardiology, University Heart and Vascular Center UKE Hamburg, Germany. AD - German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Lubeck, Germany. FAU - Ludman, Peter F AU - Ludman PF AD - Department of Cardiology, University Hospitals Birmingham, Birmingham, UK. FAU - Adnan Nadir, M AU - Adnan Nadir M AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. AD - Department of Cardiology, University Hospitals Birmingham, Birmingham, UK. FAU - Steeds, Richard P AU - Steeds RP AD - Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK. AD - Department of Cardiology, University Hospitals Birmingham, Birmingham, UK. LA - eng GR - FS/13/43/30324/BHF_/British Heart Foundation/United Kingdom GR - PG/17/30/32961/BHF_/British Heart Foundation/United Kingdom GR - PG/20/22/35093/BHF_/British Heart Foundation/United Kingdom PT - Journal Article DEP - 20211012 PL - Netherlands TA - Data Brief JT - Data in brief JID - 101654995 PMC - PMC8526959 OTO - NOTNLM OT - Mitral regurgitation OT - Myocardial infarction OT - Secondary MR OT - Valvular disease COIS- The authors declare that they have no known competing financial interests or personal relationships which have or could be perceived to have influenced the work reported in this article. Prof Myerson and Dr Sharma are supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre and Dr Sharma was also funded by the Birmingham Health Partners Research Starter Fellowship. This work was partially supported by European Union BigData@Heart (grant agreement EU IMI 116074 to Prof Kirchhof), 10.13039/501100000274British Heart Foundation (FS/13/43/30324, PG/17/30/32961, PG/20/22/35093 and AA/18/2/34218 to Prof Kirchhof), German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK, via a grant to AFNET to Prof Kirchhof) and Leducq Foundation to Prof Kirchhof. Disclosures: Prof Kirchhof receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last three years. Prof Kirchhof is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 20160. EDAT- 2021/10/28 06:00 MHDA- 2021/10/28 06:01 PMCR- 2021/10/12 CRDT- 2021/10/27 07:10 PHST- 2021/08/05 00:00 [received] PHST- 2021/09/27 00:00 [revised] PHST- 2021/10/01 00:00 [accepted] PHST- 2021/10/27 07:10 [entrez] PHST- 2021/10/28 06:00 [pubmed] PHST- 2021/10/28 06:01 [medline] PHST- 2021/10/12 00:00 [pmc-release] AID - S2352-3409(21)00733-2 [pii] AID - 107451 [pii] AID - 10.1016/j.dib.2021.107451 [doi] PST - epublish SO - Data Brief. 2021 Oct 12;39:107451. doi: 10.1016/j.dib.2021.107451. eCollection 2021 Dec.